Dr Reddy's Laboratories reported FY26 standalone turnover of ₹20,102 crore, with significant ESG progress. The company achieved fuel transition to biomass/natural gas and water positivity. Aggressive carbon reduction targets include net-zero by 2045.
Dr Reddy's Laboratories FY2026 ESG Report
Dr Reddy's Laboratories reported a standalone turnover of ₹20,102 crore for the fiscal year 2025-26. The company also highlighted substantial progress in its Environmental, Social, and Governance (ESG) initiatives.
Reader Takeaway: Strong ESG integration with operational strategy; focus on carbon neutrality and first-to-market products.
What just happened
Dr Reddy's Laboratories has released its Business Responsibility and Sustainability Reporting (BRSR) for FY2026. Key highlights include a standalone turnover of ₹20,102 crore, with ₹6,416 crore from India and ₹13,686 crore from international markets. The company has completed a significant transition of its primary fuel sources across manufacturing to biomass, briquettes, or natural gas, completely phasing out coal.
Why this matters
This report signals Dr. Reddy's commitment to integrating ESG principles into its core business. The successful fuel transition and water management initiatives (Zero Liquid Discharge at 16 sites, water positivity since FY2023) reduce operational risks and enhance long-term sustainability. The clear roadmap towards net-zero GHG emissions by FY2045 demonstrates a forward-looking approach, appealing to investors prioritizing sustainable businesses.
The backstory
Dr. Reddy's Laboratories has been progressively working on its sustainability goals. The BRSR report indicates a multi-year effort in fuel transition and water management. The company has set ambitious targets, including an 80% absolute reduction in Scope 1 & 2 emissions by FY 2030 (from FY 2023 levels).
What changes now
The report confirms operational changes, such as the complete phase-out of coal. It also reinforces the company's strategic focus on innovation, aiming for 'first-to-market' product launches, with 43% of new launches in priority markets achieving this in FY2026. The commitment to serving 1.5 billion patients by 2030 through affordability and innovation remains a key focus.
Risks to watch
While the report highlights progress, investors will watch the execution of ambitious carbon reduction targets and the cost implications of maintaining water positivity and ZLD facilities. Continued innovation to maintain a 'first-to-market' edge in competitive global pharmaceutical markets is also crucial.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
- Total Standalone Turnover: ₹20,102 crore (FY 2025-26)
- CSR Spending: ₹111.41 crore (FY 2025-26)
- Total Employees: 36,726
- Combined LTIFR: 0.04 (per million-person hours worked)
- Net-Zero Target: FY 2045
- Scope 1 & 2 Emissions Reduction Target: 80% by FY 2030 (vs FY 2023)
What to track next
Investors should monitor Dr. Reddy's progress against its decarbonization targets, especially Scope 1, 2, and 3 emissions data in future reports. Progress on gender parity targets, particularly reaching 35% women in senior leadership by 2030, and the success rate of 'first-to-market' product launches will also be key indicators.